Healthcare Industry Developments | BioTuesdays by Kilmer Lucas IR

Developments

IP Australia grants Klotho 18 claims for s-KL

Klotho Neurosciences (NASDAQ: KLTO) has announced that IP Australia has accepted 18 claims within its patent application covering the composition and use of its human secreted Klotho protein, s-KL isoform. The patent...

February 18, 2026

Developments

Bioxytran reports positive Phase 2 data for ProLectin-M

Bioxytran (OTCQB: BIXT) has announced positive clinical results from its recently completed Phase 2 randomized, double-blind, placebo-controlled, dose-optimization trial evaluating ProLectin-M in subjects with...

February 13, 2026

Developments

FDA clears Precision’s IND for PBGENE-DMD

Precision BioSciences (NASDAQ: DTIL) has announced that the FDA has granted a Study May Proceed notification, allowing initiation of clinical trial site activation for the Phase 1/2 FUNCTION-DMD trial of PBGENE-DMD in...

February 13, 2026

Developments

INOVAIT honors Profound with 2025/26 Mount Logan Award recognizing Tulsa Procedure for prostate disease

Profound Medical (NASDAQ: PROF; TSX: PRN) has announced that it has received the 2025/2026 Mount Logan Award from INOVAIT, the Canadian national network for commercializing breakthroughs in image-guided therapy and AI...

February 12, 2026

Developments

BioSyent to acquire Oral Science

BioSyent (TSXV: RX) has entered into a Share Purchase Agreement to acquire closely held Oral Science, a Canadian distributor of specialized healthcare products for dental hygiene and oral health based in Brossard...

February 10, 2026

Developments

PreveCeutical files patent for delivery of CNS-active agents

PreveCeutical Medical (CSE: PREV; OTCQB: PRVCF) has filed an international patent application for the delivery of CNS-active therapeutic agents covering methods and formulations aimed at addressing treatment challenges...

February 9, 2026

Developments

Exicure reports publication highlighting Phase 2 burixafor data showing rapid stem cell mobilization

Exicure (NASDAQ: XCUR) announced that Annals of Hematology has published results from a Phase 2 clinical study demonstrating rapid stem cell mobilization with burixafor (GPC-100/TG-0054)—a highly selective CXCR4...

February 6, 2026

Developments

Cognition lengthens Zervimesine program in DLB

Cognition Therapeutics (NASDAQ: CGTX) has extended the duration of the expanded access program (EAP) for dementia with Lewy bodies (DLB) from the original 12 months to include several more months of treatment. According...

February 6, 2026

Developments

PRO FAMILIA and Profound mark 500 Sonalleve Procedures; expand access to incision-free women’s healthcare

Profound Medical (NASDAQ:PROF; TSX:PRN) announced today that PRO FAMILIA Specialist Hospital in Rzeszów, Poland has completed its 500th Sonalleve Procedure. The MRI-guided therapy provides women with a non-surgical...

February 5, 2026

Developments

JPO grants patent to Marvel for MB-204

Marvel Biosciences (TSXV: MRVL; OTCQB: MBCOF) has been granted a patent for its lead therapeutic candidate MB-204 by the Japanese Patent Office (JPO) covering composition of matter and methods of use claims. MB-204 is a...

February 4, 2026

Developments

FDA grants Fast Track Designation to Cumberland’s ifetroban DMD program

Cumberland Pharmaceuticals (NASDAQ: CPIX) has received Fast Track Designation from the FDA for its novel oral therapy targeting a fatal form of heart disease in Duchenne muscular dystrophy (DMD) patients. The FDA has...

February 4, 2026

Developments

FDA clears Nanox’s TAP2D image enhancement technology

Nanox (NASDAQ: NNOX) has announced receiving FDA 510(k) clearance for TAP2D, a new cloud-enabled image enhancement capability for the Nanox.ARC and Nanox.ARC X digital tomosynthesis systems. According to Nanox, the FDA...

February 3, 2026

Developments

USPTO grants Acurx Pharmaceuticals patent for DNA Polymerase IIIC inhibitors

Acurx Pharmaceuticals (NASDAQ: ACXP) has been granted a new patent by the U.S. Patent and Trademark Office (USPTO) covering DNA Polymerase IIIC inhibitors including compositions of matter, methods of use, and...

February 2, 2026

Developments

Publication supports scientific rationale for Palvella’s QTORIN in DSAP

Palvella Therapeutics (NASDAQ: PVLA) announced that Clinical and Experimental Dermatology has published a peer-reviewed systematic review synthesizing clinical evidence on off-label topical statin use in porokeratosis...

February 2, 2026

Developments

Kazia reveals compelling data on nuclear PD-L1 degrader NDL2

Kazia Therapeutics (NASDAQ: KZIA) has announced compelling preclinical and translational data supporting the development of NDL2, a potentially first-in-class protein degrader designed to selectively eliminate nuclear...

January 30, 2026

Developments

Immunotherapy review highlights Faron’s bexmarilimab in immune-resistant cancer

Faron Pharmaceuticals (AIM: FARN; First North: FARON) has announced the publication of a comprehensive review article in the peer-reviewed journal Immunotherapy detailing the potential of the company’s lead candidate...

January 29, 2026

Developments

OSE expands lusvertikimab into new immune-mediated indications

OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) has announced that it has selected chronic pouchitis and hidradenitis suppurativa (HS) as new key indications for lusvertikimab, a potential first-in-class IL-7R...

January 29, 2026

Developments

FDA certifies LSL’s ophthalmic ointment manufacturing for U.S. market

LSL Pharma (TSXV: LSL) has announced that the FDA has certified the ophthalmic ointment manufacturing operations of its subsidiary, Steri-Med Pharma, clearing the company to commercialize ophthalmic ointment products in...

January 28, 2026

Developments

FDA grants En Carta BDD for EC Pocket Lyme test

Closely held En Carta Diagnostics has announced that its EC Pocket Lyme test for the early detection of Borrelia bacteria—the cause of Lyme disease—has received Breakthrough Design Designation (BDD) from the FDA. EC...

January 28, 2026

Developments

Omeros launches first commercial sales of YARTEMLEA for TA-TMA

Omeros (NASDAQ: OMER) has announced that it has completed its first commercial shipments of YARTEMLEA to distributors for the treatment of adult and pediatric patients with stem cell transplant-associated thrombotic...

January 27, 2026

Developments

Ernexa chosen as one of ten for JETRO acceleration program

Ernexa Therapeutics (NASDAQ: ERNA) has announced it was selected as one of only ten global companies to participate in the prestigious Japan Entry Acceleration Program (JEAP) by the Japan External Trade Organization...

January 27, 2026

Developments

Pluri completes first phase of placenta-derived biomaterials program

Pluri (NASDAQ, TASE: PLUR) has announced the completion of the first phase of its program with closely held Resbiomed Technologies OOD, a European biotechnology company developing extracellular-matrix- based...

January 22, 2026

Subscribe